SCHEMBL5947640

SCHEMBL5947640

c1ccc(Cc2cccc(CNCCc3c[nH]c4ccccc34)c2)cc1

nearest known ligand 0.78

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 6/20 0.69
▸ MC5R P33032 2/20 0.67
▸ MC3R P41968 2/20 0.67
▸ MC1R Q01726 2/20 0.67
▸ MEN1 O00255 3/20 0.61
▸ LMNA P02545 2/20 0.61
▸ TP53 P04637 1/20 0.61
▸ HTR2A P28223 4/20 0.57
▸ HTR6 P50406 4/20 0.57
▸ HTR1A P08908 2/20 0.56
▸ KDM4E B2RXH2 1/20 0.56
▸ ALDH1A1 P00352 1/20 0.56
▸ HTT P42858 1/20 0.56
▸ DRD2 P14416 1/20 0.55
▸ HTR7 P34969 1/20 0.55
▸ MITF O75030 1/20 0.54
▸ MAPT P10636 1/20 0.54
▸ MAPK1 P28482 1/20 0.54
▸ G6PD P11413 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL830201 0.88 MC5R (0.79) KMT2AMC5RMC3RMC1RMEN1
Hydrochloric Acid SCHEMBL11188453 0.86 MC5R (0.77) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL5947273 0.85 KMT2A (0.66) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL5947468 0.85 HTR6 (0.74) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL14426460 0.85 KMT2A (0.72) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL23745814 0.85 KMT2A (0.69) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL5947340 0.84 HTR2A (0.83) KMT2AMEN1HTR2AHTR6HTR1A
SCHEMBL5947558 0.84 KMT2A (0.65) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL5947571 0.84 KMT2A (0.79) KMT2AMC5RMC3RMC1RMEN1
SCHEMBL27595961 0.84 KMT2A (0.65) KMT2AMC5RMC3RMC1RMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor CHEN ZHAOGEN 2006-01-12 — — US claimed
CN-1610547-A N-(2-arylethyl)benzylamines as antagonists of the 5-HT6 receptor LILLY CO ELI (US) 2005-04-27 — — CN claimed
EP-1379239-A2 N-(2-ARYLETHYL) BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2004-01-14 — — EP claimed
WO-2002078693-A2 N-(2-ARYLETHYL)BENZYLAMINES AS ANTAGONISTS OF THE 5-HT6 RECEPTOR ELI LILLY AND COMPANY (US) 2002-10-10 — — WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060009511-A9 N-(2-arylethyl) benzylamines as antagonists of the 5-ht6 receptor HTR6, HTR2C, HTR1B KMT2A 1269/4885MC5R 50/4885MC3R 86/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback